Strontium ranelate

Research use only, not for human use.

A strontium(II) salt of ranelic acid that stimulates CaSR and leads to the differentiation of pre-osteoblast to osteoblast, increases the bone formation; also stimulates osteoblasts to secrete osteoprotegerin in inhibiting osteoclasts formed from pre-osteoclasts in relation to the RANKL system.

A strontium(II) salt of ranelic acid that stimulates CaSR and leads to the differentiation of pre-osteoblast to osteoblast, increases the bone formation; also stimulates osteoblasts to secrete osteoprotegerin in inhibiting osteoclasts formed from pre-osteoclasts in relation to the RANKL system; a medication for osteoporosis treatment.Osteoporosis Approved.

Strontium Ranelate (0.1-1 mM; 22 days; Mouse calvaria cells) treatment shows the expression of mRNA for early osteoblast markers (alkaline phosphatase, ALP) is visualized by day 5, while late markers (osteocalcin, OCN) are detectable only by day 15 and beyond.Strontium Ranelate (0.1-1 mM; 22 days; Mouse calvaria cells) treatment results in significantly increases the mRNA expression of the osteoblastic markers ALP, BSP and OCN at day 22 of MC cell culture.Strontium Ranelate is found to increase alkaline phosphatase activity and prostaglandin E2 production in a COX-2 dependent manner in murine marrow stromal cells. RT-PCRCell Line:Mouse calvaria (MC) cells Concentration:0.1 mM, 0.3 mM or 1 mMIncubation Time:22 daysResult:The expression of mRNA for early osteoblast markers (ALP) was visualized by day 5, while late markers (OCN) were detectable only by day 15 and beyond.Western Blot AnalysisCell Line:Mouse calvaria (MC) cells Concentration:0.1 mM, 0.3 mM or 1 mMIncubation Time:22 days Result:Significantly increased the mRNA expression of the osteoblastic markers ALP, BSP and OCN at day 22 of MC cell culture.

Strontium Ranelate increases bone formation and decreased bone resorption, which results in increased bone mass in the vertebrae of intact adult mice. In intact adult rats, Strontium Ranelate also increases bone mass, as measured by dual-energy X-ray absorptiometry, in lumbar vertebra and femur, and this is confirmed by histological assessment of trabecular bone volume in the tibial metaphysis.Strontium Ranelate is found to decrease bone resorption and to increase bone formation in alveolar bone in normal adult monkeys (Macaca fascicularis), which exhibits extensive bone remodeling.In ovariectomized rats, short-term (3 months) treatment with Strontium Ranelate prevents trabecular bone loss induced by oestrogen deficiency, as demonstrated by bone ash, bone mineral content and histomorphometric analysis in the tibial metaphysis. This effect results from decreased bone resorption while bone formation was maintained. These beneficial effects of Strontium Ranelate on bone mass and microarchitecture in ovariectomized rats are confirmed in long-term experiments. In this long-term study (2 years), the increase in bone mass and microarchitecture induced by Strontium Ranelate results in a marked improvement in bone strength, supporting the beneficial effect of this drug on bone resistance.

Distrontium renelate | S-12911

GPCR/G Protein

CaSR

CalciumChannel

Metabolic Disease

Osteoporosis

135459-87-9

513.4896

C12H6N2O8SSr2

>98% (HPLC)

DMSO: < 1 mg/mL

O=C([O-])CC1=C(C([O-])=O)SC(N(CC([O-])=O)CC([O-])=O)=C1C#N.[Sr+2].[Sr+2]

3-Thiopheneacetic acid, 5-[bis(carboxymethyl)amino]-2-carboxy-4-cyano-, strontium salt (1:2)

(-20℃)

With Ice Pack

≥ 2 years